lncRNA PVT1 in cancer: A review and meta-analysis

Clinica Chimica Acta

Volumn 474, Issue , 2017, Pages 1-7

  Lu, Dapeng ^a   Luo, Peng ^a   Wang, Qi ^a   Ye, Yuanyuan ^a   Wang, Baolong ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathological characteristics; Long non coding RNA; Overall survival; PVT1

Indexed keywords

LONG UNTRANSLATED RNA; PLASMACYTOMA VARIANT TRANSLOCATION 1; UNCLASSIFIED DRUG; PVT1 LONG-NON-CODING RNA, HUMAN;

CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; MALIGNANT NEOPLASM; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TUMOR DIFFERENTIATION; TUMOR VOLUME; GENE EXPRESSION REGULATION; GENETICS; META ANALYSIS; NEOPLASM; PATHOLOGY;

DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; NEOPLASMS; RNA, LONG NONCODING;

EID: 85028729229     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2017.08.038     Document Type: Review

References (51)

1. Ferlay, J., Soerjomataram, I., Dikshit, R. et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–386.
2. Hsieh, H.J., Peng, G., Cellular responses to replication stress: implications in cancer biology and therapy. DNA Repair 49 (2017), 9–20.
3. Yang, K., Park, W., Huh, S.J., Bae, D.S., Kim, B.G., Lee, J.W., Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer. J. Radiat. Oncol. 35 (2017), 39–47.
4. Barton, M.B., Frommer, M., Shafiq, J., Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol. 7 (2006), 584–595.
5. Cree, I.A., Kurbacher, C.M., Lamont, A., Hindley, A.C., Love, S., Group TCAOCT. A, Prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anti-Cancer Drugs 18 (2007), 1093–1101.
6. Shi, Y., Li, J., Liu, Y. et al., The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression. Mol. Cancer, 14, 2015, 51.
7. Han, L., Zhang, E.B., Yin, D.D. et al., Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. Cell Death Dis., 6, 2015, e1665.
8. Hu, L., Wu, Y., Tan, D. et al., Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma. J. Exp. Clin. Cancer Res., 34, 2015, 7.
9. Zhang, E.B., Kong, R., Yin, D.D. et al., Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget 5 (2014), 2276–2292.
10. Ren, S., Liu, Y., Xu, W. et al., Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J. Urol. 190 (2013), 2278–2287.
11. Mercer, T.R., Dinger, M.E., Mattick, J.S., Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10 (2009), 155–159.
12. Zhang, J., Zhang, A., Wang, Y. et al., New insights into the roles of ncRNA in the STAT3 pathway. Future Oncol. 8 (2012), 723–730.
13. Feng, J., Bi, C., Clark, B.S., Mady, R., Shah, P., Kohtz, J.D., The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a dlx-2 transcriptional coactivator. Genes Dev. 20 (2006), 1470–1484.
14. Zeidler, R., Joos, S., Delecluse, H.J. et al., Breakpoints of Burkitt's lymphoma t(8;22) translocations map within a distance of 300 kb downstream of MYC. Genes Chromosom. Cancer 9 (1994), 282–287.
15. Shen, C.J., Cheng, Y.M., Wang, C.L., LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemo resistance in cervical cancer cells. J. Drug Target. 25 (2017), 637–644.
16. Chen, X., Gao, G., Liu, S. et al., Long noncoding RNA PVT1 as a novel diagnostic biomarker and therapeutic target for melanoma. Biomed. Res. Int., 7038579, 2017, 2017.
17. Liu, H.T., Fang, L., Cheng, Y.X. et al., LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a. Cancer Med. 5 (2016), 3512–3519.
18. Tierney, J.F., Stewart, L.A., Ghersi, D. et al., Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 2007, 16.
19. Parmar, M.K., Torri, V., Stewart, L., Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 17 (1998), 2815–2834.
20. Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25 (2010), 603–605.
21. Sterne, J.A., Egger, M., Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J. Clin. Epidemiol. 54 (2001), 1046–1055.
22. Yuan, C.L., Li, H., Zhu, L., Liu, Z., Zhou, J., Shu, Y., Aberrant expression of long noncoding RNA PVT1 and its diagnostic and prognostic significance in patients with gastric cancer. Neoplasma 63 (2016), 442–449.
23. Takahashi, Y., Sawada, G., Kurashige, J. et al., Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br. J. Cancer 110 (2014), 164–171.
24. Chen, J., Li, Y., Zheng, Q. et al., Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett. 388 (2017), 208–219.
25. Ding, J., Li, D., Gong, M. et al., Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer. OncoTargets and Therapy 7 (2014), 1625–1630.
26. Zheng, X., Hu, H., Li, S., High expression of lncRNA PVT1 promotes invasion by inducing epithelial-to-mesenchymal transition in esophageal cancer. Oncol. Lett. 12 (2016), 2357–2362.
27. Huang, C., Yu, W., Wang, Q. et al., Increased expression of the lncRNA PVT1 is associated with poor prognosis in pancreatic cancer patients. Minerva Med. 106 (2015), 143–149.
28. Yang, Y.R., Zang, S.Z., Zhong, C.L., Li, Y.X., Zhao, S.S., Feng, X.J., Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 7 (2014), 6929–6935.
29. Huang, C., Liu, S., Wang, H., Zhang, Z., Yang, Q., Gao, F., LncRNA PVT1 overexpression is a poor prognostic biomarker and regulates migration and invasion in small cell lung cancer. Am. J. Transl. Res. 8 (2016), 5025–5034.
30. Cui, D., CH, Yu, Liu, M., Xia, Q.Q., Zhang, Y.F., Jiang, W.L., Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer. Tumour Biol. 37 (2016), 4127–4134.
31. Wan, L., Sun, M., Liu, G.J. et al., Long noncoding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression. Mol. Cancer Ther. 15 (2016), 1082–1094.
32. Kong, R., Zhang, E.B., Yin, D.D. et al., Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol. Cancer, 14, 2015, 82.
33. Wang, F., Yuan, J.H., Wang, S.B. et al., Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology 60 (2014), 1278–1290.
34. Zhuang, C., Li, J., Liu, Y. et al., Tetracycline-inducible shRNA targeting long non-coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells. Oncotarget 6 (2015), 41194–41203.
35. Huang, T., Liu, H.W., Chen, J.Q. et al., The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer. Biomed. Pharmacother. 88 (2017), 302–308.
36. Li, P.D., JL, Hu, Ma, C. et al., Upregulation of the long non-coding RNA PVT1 promotes esophageal squamous cell carcinoma progression by acting as a molecular sponge of miR-203 and LASP1. Oncotarget 8 (2017), 34164–34176.
37. Ebisuya, M., Yamamoto, T., Nakajima, M. et al., Ripples from neighbouring transcription. Nat. Cell Biol. 10 (2008), 1106–1113.
38. Shi, X., Sun, M., Liu, H. et al., Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 339 (2013), 159–166.
39. Ding, C., Yang, Z., Lv, Z. et al., Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients. Oncol. Lett. 9 (2015), 955–963.
40. Gao, Y.L., Zhao, Z.S., Zhang, M.Y., Han, L.J., Dong, Y.J., Xu, B., Long non-coding RNA PVT1 facilitates cervical cancer progression via negative regulating of miR-424. Oncol. Res., 2017.
41. Wu, Y., Wang, Y.Q., Weng, W.W. et al., A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls. Oncogene, e192, 2016, 5.
42. Zhou, Q., Chen, J., Feng, J., Wang, J., Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumour Biol. 37 (2016), 3105–3113.
43. Ma, Y., Wang, P., Xue, Y. et al., PVT1 affects growth of glioma microvascular endothelial cells by negatively regulating miR-186. Tumour Biol., 39, 2017, 1010428317694326.
44. BQ, Wu, Jiang, Y., Zhu, F. et al., Long noncoding RNA PVT1 promotes EMT and cell proliferation and migration through downregulating p21 in pancreatic cancer cells. Technol. Cancer Res. Treat., 2017, 1533034617700559.
45. Zhang, S., Zhang, G., Liu, J., Long noncoding RNA PVT1 promotes cervical cancer progression through epigenetically silencing miR-200b. Acta Pathol. Microbiol. Immunol. Scand. 124 (2016), 649–658.
46. Lancaster, J.M., Dressman, H.K., Whitaker, R.S. et al., Gene expression patterns that characterize advanced stage serous ovarian cancers. J. Soc. Gynecol. Investig. 11 (2004), 51–59.
47. Guan, Y., Kuo, W.L., Stilwell, J.L. et al., Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin. Cancer Res. 13 (2007), 5745–5755.
48. Huppi, K., Siwarski, D., Skurla, R. et al., Pvt-1 transcripts are found in normal tissues and are altered by reciprocal (6;15) translocations in mouse plasmacytomas. Proc. Natl. Acad. Sci. U. S. A. 87 (1990), 6964–6968.
49. Shtivelman, E., Bishop, J.M., Effects of translocations on transcription from PVT. Mol. Cell. Biol. 10 (1990), 1835–1839.
50. Borg, A., Baldetorp, B., Ferno, M. et al., c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int. J. Cancer 51 (1992), 687–691.
51. You, L., Chang, D., HZ, Du et al., Genome-wide screen identifies PVT1 as a regulator of gemcitabine sensitivity in human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 407 (2011), 1–6.